You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes
|
|---|---|
| Published in |
Molecular Medicine, November 2014
|
| DOI | 10.2119/molmed.2014.00215 |
| Pubmed ID | |
| Authors |
Michael Brines, Ann N. Dunne, Monique van Velzen, Paolo L. Proto, Claes-Goran Ostenson, Rita I. Kirk, Ioannis N. Petropoulos, Saad Javed, Rayaz A. Malik, Anthony Cerami, Albert Dahan |
| Abstract |
Although erythropoietin ameliorates experimental type 2 diabetes with neuropathy, serious side effects limit its potential clinical use. ARA 290, a nonhematopoietic peptide designed from the structure of erythropoietin, interacts selectively with the innate repair receptor that mediates tissue protection. ARA 290 has shown efficacy in preclinical and clinical studies of metabolic control and neuropathy. To evaluate the potential activity of ARA 290 in type 2 diabetes and painful neuropathy, subjects were enrolled in this phase 2 study. ARA 290 (4 mg) or placebo were self-administered subcutaneously daily for 28 d and the subjects followed for an additional month without further treatment. No potential safety issues were identified. Subjects receiving ARA 290 exhibited an improvement in hemoglobin A(1c) (Hb A(1c)) and lipid profiles throughout the 56 d observation period. Neuropathic symptoms as assessed by the PainDetect questionnaire improved significantly in the ARA 290 group. Mean corneal nerve fiber density (CNFD) was reduced significantly compared with normal controls and subjects with a mean CNFD >1 standard deviation from normal showed a significant increase in CNFD compared with no change in the placebo group. These observations suggest that ARA 290 may benefit both metabolic control and neuropathy in subjects with type 2 diabetes and deserves continued clinical evaluation. |
X Demographics
The data shown below were collected from the profiles of 24 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 7 | 29% |
| United Kingdom | 4 | 17% |
| Palestine, State of | 1 | 4% |
| India | 1 | 4% |
| Unknown | 11 | 46% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 22 | 92% |
| Practitioners (doctors, other healthcare professionals) | 1 | 4% |
| Scientists | 1 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 75 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Hungary | 1 | 1% |
| Italy | 1 | 1% |
| Unknown | 73 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 13 | 17% |
| Researcher | 8 | 11% |
| Other | 6 | 8% |
| Student > Ph. D. Student | 6 | 8% |
| Lecturer | 4 | 5% |
| Other | 19 | 25% |
| Unknown | 19 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 27 | 36% |
| Nursing and Health Professions | 6 | 8% |
| Biochemistry, Genetics and Molecular Biology | 4 | 5% |
| Unspecified | 4 | 5% |
| Agricultural and Biological Sciences | 3 | 4% |
| Other | 10 | 13% |
| Unknown | 21 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 30. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 March 2024.
All research outputs
#1,334,973
of 25,757,133 outputs
Outputs from Molecular Medicine
#39
of 1,212 outputs
Outputs of similar age
#15,035
of 277,249 outputs
Outputs of similar age from Molecular Medicine
#2
of 16 outputs
Altmetric has tracked 25,757,133 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,212 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.9. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 277,249 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.